Table 5.

Efficacy outcomes from the double-blind period

		Paliperidone	p Value
Efficacy measure	PP	ER	(paliperidone ER vs PP)
PANSS total score	n = 191	n = 104
Double-blind baseline mean (SD)	50.8 (10.9)	51.0 (11.4)
LS mean (SE) change from baseline to end point	2.5 (0.9)	6.0 (1.3)	0.025
PSP score	n = 188	n = 103
Double-blind baseline mean (SD)	72.7 (10.5)	70.8 (10.9)
LS mean (SE) change from baseline to end point	−1.4 (0.8)	−3.3 (1.1)	0.156
CGI-S score	n = 191	n = 104
Double-blind baseline mean (SD)	2.6 (0.8)	2.6 (0.8)
LS mean (SE) change from baseline to end point	0.2 (0.1)	0.3 (0.1)	0.095

CGI-S Clinical Global Impressions–Severity, ER extended release, LS least squares, PANSS Positive and Negative Syndrome Scale, PP paliperidone palmitate, PSP Personal and Social Performance, SD standard deviation, SE standard error.